Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2006 Aug 21;12(31):5078-80.
doi: 10.3748/wjg.v12.i31.5078.

Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?

Carmen Verge  1 , M Isabel Lucena, Enrique López-Torres, M José Puche-Garcia, Enrique Fraga, Manuel Romero-Gomez, Raúl J Andrade
Affiliations
Case Reports

Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?

Carmen Verge et al. World J Gastroenterol. .

Abstract

Disulfiram and calcium carbimide are two alcohol deterrants widely used in alcoholism treatment, however, there exist great concerns over their safety. Reports on hepatotoxicity, mainly related to disulfiram therapy, have been published. The hepatotoxic potential of calcium carbimide is less well characterized. Here, we describe four cases of liver damage related to this therapeutic group that were submitted to a Registry of hepatotoxicity and point out the limitations that we face when prescribing these compounds. A reassessment of the role of these compounds in the management of alcohol dependence is clearly needed.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Peachey JE, Brien JF, Roach CA, Loomis CW. A comparative review of the pharmacological and toxicological properties of disulfiram and calcium carbimide. J Clin Psychopharmacol. 1981;1:21–26. - PubMed
    1. Moreno A, Vazquez JJ, Ruizdel Arbol L, Guillen FJ, Colina F. Structural hepatic changes associated with cyanamide treatment: cholangiolar proliferation, fibrosis and cirrhosis. Liver. 1984;4:15–21. - PubMed
    1. Mason NA. Disulfiram-induced hepatitis: case report and review of the literature. DICP. 1989;23:872–875. - PubMed
    1. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006;44:791–797. - PubMed
    1. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521. - PubMed

Publication types